Nexavar and Vitrakvi
Determining the interaction of Nexavar and Vitrakvi and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Based on in vitro inhibition data, coadministration with sorafenib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by sorafenib. MANAGEMENT: Caution is advised when sorafenib is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever sorafenib is added to or withdrawn from therapy. References "Product Information. Nexavar (sorafenib)." Bayer Pharmaceutical Inc, West Haven, CT. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Professional:MONITOR: Based on in vitro inhibition data, coadministration with sorafenib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by sorafenib.
MANAGEMENT: Caution is advised when sorafenib is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever sorafenib is added to or withdrawn from therapy.
- "Product Information. Nexavar (sorafenib)." Bayer Pharmaceutical Inc, West Haven, CT.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Nexavar-Vitrakvi (Larotrectinib Capsules)
- Nexavar-Vitrakvi (Larotrectinib Oral Solution)
- Nexavar-Vitrase
- Nexavar-Vitrase injection
- Nexavar-Vitravene
- Nexavar-Vitron-C
- Vitrakvi-Nexesta Fe
- Vitrakvi-Nexiclon XR
- Vitrakvi-Nexiclon XR Suspension
- Vitrakvi-Nexium
- Vitrakvi-Nexium (Esomeprazole Delayed-Release Capsules)
- Vitrakvi-Nexium (Esomeprazole Powder for Suspension)